![Pharm-Rx Dextromethorphan Hydrobromide](https://www.pharmacompass.com/image/flap/pharm-rx-dextromethorphan-hydrobromide-desktop-headergif-25717.gif)
![Pharm-Rx Dextromethorphan Hydrobromide](https://www.pharmacompass.com/image/flap/pharm-rx-dextromethorphan-hydrobromidegif-73965.gif)
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
EU WC
Listed Suppliers
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
AUVELITY is a novel, oral, NMDA receptor antagonist with multimodal activity approved for the treatment of MDD in adults. AUVELITY is a proprietary extended-release oral tablet containing dextromethorphan HBr (45 mg) and bupropion HCl (105 mg).
Lead Product(s): Dextromethorphan Hydrobromide,Bupropion Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Auvelity
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2022
Details:
AUVELITY (dextromethorphan hydrobromide) is the first and only rapid-acting oral treatment approved with labeling of statistically significant improvement in depressive symptoms compared to placebo starting at one week.
Lead Product(s): Dextromethorphan Hydrobromide,Bupropion Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Auvelity
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 19, 2022
Details:
This diverse portfolio of products includes Breathe Right® Nasal Strips, the world’s #1 nasal strip, and Children’s Dimetapp®, the #1 pharmacist-recommended brand for children's cough and cold products, as well as Anbesol®, Alavert®, Dristan®, Primatene Tablets® and FiberCon®.
Lead Product(s): Brompheniramine Maleate,Dextromethorphan Hydrobromide,Phenylephrine Hydrochloride
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Dimetapp
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Foundation Consumer Healthcare
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 16, 2020